nucleosome diagnostics
Volition Eyes East Asia Expansion With Nucleosome-Based Blood Test for Lung Cancer Screening
Premium
The firm hopes to include its lung cancer assay in Taiwan's national cancer screening program while developing sepsis and ovarian cancer assays.
VolitionRx Signs on Diagnostic Oncology CRO for Clinical Studies of Cancer, Sepsis Tests
DXOCRO will conduct large-scale clinical utility studies of Volition's Nu.Q NETs and Nu.Q Cancer tests at multiple sites in the US.
VolitionRx Secures $1.5M Loan From Namur Invest Capital Risk
The non-dilutive funding will go toward an early-access program for Volition's Nu.Q nucleosome quantification technology in the US, EU, and UK.
VolitionRx Signs on Sage Healthcare as Distributor for Canine Cancer Test in Asia
The Nu.Q Vet Cancer Test is an ELISA-based blood test that identifies and measures circulating nucleosomes, an early cancer marker.
Delfi Diagnostics Nets $100M in Series A Financing, Plans Multi-Cancer Screening Test
The company intends to develop its fragmentomic approach for early cancer detection both in individual tumor types and for multi-cancer screening.